The Spanish COPD guidelines recommend treatment of the mixed COPD–asthma phenotype with ICS and ... long-acting muscarinic receptor antagonists (LAMA) to ICS + long-acting b2 agonist (LABA ...

If you have asthma, running might worsen your symptoms, but there are precautions you can take to make it safer. Typically, symptoms like wheezing, coughing, and shortness of breath begin about 15 ...

Penpa Tsering has said that the Dalai Lama's actions have been misinterpreted A top Tibetan leader has defended the Dalai Lama over a video that showed him asking a child to suck his tongue.

another LABA/LAMA/ICS combination – is approved for chronic obstructive pulmonary disease (COPD) but was only filed for approval as an asthma therapy in Europe in February, so looks set to be ...

He is, without a doubt, one of the best-known people on the planet. In an age where celebrity is worshipped, the Dalai Lama is a faith leader who has become a spiritual superstar. As he approaches ...

Asthma is the most common chronic disease of childhood and, in the latter part of the 20th century, reached epidemic proportions. Asthma is generally believed to result from gene-environment ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Philip Morris International has agreed to sell its Vectura asthma inhaler maker for only a third of what it ...

Their analysis shows that children's risk of developing asthma later in life can be more reliably predicted by observing the dynamic development of symptoms during the first year of life.

The global airway disease treatment market is projected to experience significant growth over the next decade, with revenue ...

Lama Fakih is Human Rights Watch’s Middle East and North Africa director and the director of the Beirut office. Prior to her current role, Fakih was the Director of the Crisis and Conflict ...

Specifically, the approval covers patients already on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), or on a ...

The global asthma treatment market size was valued at USD 27.51 billion in 2023 and is expected to reach around USD 35.93 billion by 2034. It is growing at a CAGR of 2.42% from 2024 and 2034. The ...